ExploreWatchlistsPricing
  1. JP-listed companies
  2. Takeda Pharmaceutical Company Limited
  3. Financials
  4. EBITDA

Takeda Pharmaceutical Company Limited (4502)

Market cap
¥8.92T
P/E ratio
57.3x
Takeda develops and manufactures innovative medicines for gastrointestinal diseases, rare diseases, oncology, neuroscience, vaccines, and plasma therapies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Mar 31, 20251,103,982+17.19%
Mar 31, 2024942,077-18.43%
Mar 31, 20231,154,905+10.62%
Mar 31, 20221,043,995-2.33%
Mar 31, 20211,068,940+56.26%
Mar 31, 2020684,057+43.28%
Mar 31, 2019477,415+91.07%
Mar 31, 2018249,863

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat